MMV was involved in a number of sessions at the ASTMH in Philadelphia. Presentations from some of the sessions are already available below.
Download a listing of all MMV symposia (PDF)
SUN 4 NOV
10:00 am to 03:00 pm
MMV Drug Combination Science Meeting - "Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to identify Parasite Populations," chaired by Marcel Tanner, Swiss Tropical Institute (STI)
WHY: The aim of this meeting is to assist MMV in designing it drug discovery program in order to fund research targeted at producing the next generation Anti-Malarial Drug Combinations post ACTs. Its is intended that one of the outcomes of the meeting will be reference paper to be used by drug developers and funding organizations in formulating their research priorities.
SPEAKERS: Phil Rosenthal; David Fidock; Marcel Tanner; Barry Clifton; David Roos; Akhil Vaidya.
MON 5 NOV
08:00 - 09:45 am
Artemether/Lumefantrine Dispersible - ACTs Addressing Children’s Therapeutic Needs, chaired by Nadia El Nasry, Novartis
WHY: Malaria is primarily a disease of infants and young children. However, there are currently no safe and effective antimalarials specifically formulated for this vulnerable population that are registered to a stringent international standard and recommended by WHO. To address this critical gap, MMV and Novartis joined forces to develop an innovative formulation of the effective fixed-dose formulation of the ACT, artemether/lumefantrine.
SPEAKERS: Michael M Makanga, Chris Hentschel, Salim Abdulla, Bernhardts R Ogutu, Philip G Sasi, Umberto D’Alessandro
10:15 am - 12:00 noon
Scaling Up ACTs - the challenge of monitoring and ensuring safety, and developing an effective surveillance system in malaria endemic regions, chaired by Anna Wang, MMV and Charles M’Gone, EDCTP
WHY: As Artemisinin-based Combination Therapies begin to be widely used in malaria endemic countries, the public health community is faced with a formidable challenge of monitoring their safety. As these new drugs have only been carefully trialed in controlled setting in less than a few thousands patients for each drug, only an effective surveillance system will be able to pick up rare and serious adverse events. ACTs are currently not recommended for pregnant women in their first trimester, what are the data in embryo toxicity and what are their implications? How can a pregnancy exposure registry assist in monitoring the safety of ACTs?
SPEAKERS: Robert Clark; Feiko O ter Kuile; Alex Dodoo and Fred Binka.
03:45 pm - 05:30 pm
Medicines for Malaria Venture’s (MMV’s) Drug Discovery Portfolio, chaired by Ian Bathurst, MMV and Win Gutteridge, Chair, MMV ESAC
WHY: MMV is funding a number of discovery research projects aimed at designing new drugs for the treatment of malaria. The aim of the Symposium is to demonstrate how molecular biologists, parasitologists, biophysicists, medicinal chemists and pharmacists work together to seek to accomplish such goals.It will indicate that modern genomics, combinatorial chemistry and high throughput screening have revolutionised the process. At the same time, it will show how, despite such advances, projects are time-consuming, costly and highly speculative.
SPEAKERS: Yongyuth Yuthavong, Susan Charman, Sanjay Desai, Domingo Gargallo.
Introduction to MMV’s Drug Discovery Portfolio
Synthetic Peroxides: A Viable Alternative to Artemisinins for the Treatment of Uncomplicated Malaria? Susan A. Charman, Monash University, Australia
Novel Inhibitors of Malarial Dihydrofolate Reductase (DHFR), Yongyuth Yuthavong, BIOTEC, Thailand
Plasmodial surface anion channel (PSAC) antagonists as lead compounds for antimalarial development, Sanjay Desai, MVR/NIAID, NIH, USA
4(1H)-Pyridones as putative antimalarials, Domingo Gargallo, Diseases of Developing World R&D Center, GlaxoSmithKline
TUES 6 NOV
05.00 pm - 06:45 pm
Bridging the Access Gap: Countries Prepare to Ensure Prompt Access to New Antimalarials, chaired by Chris Hentschel, MMV and Richard Sketetee, MACEPA
WHY: Artemisinin Combination Therapy (ACT) deployment today is primarily through the public sector, whose reach is limited in many countries. Measures are urgently needed to ensure that patients promptly receive the new medicines for malaria.
SPEAKERS: Richard Steketee, Pascalina Chanda, Ambrose Talisuna, Chris Hentschel
Introduction to Bridging the Access Gap: Preparing to ensure prompt access to new antimalarial
Beyond the public sector: Lessons learned through early ACT deployment in Zambia, Pascalina Chanda, Operations Research Officer, National Malaria Control Center, Zambia
Science Supporting Access, Chris Hentschel, MMV President and CEO
Pulling in the private informal sector in Uganda MOH Uganda-MMV pilot, Ambrose Talisuna, Ministry of Health, Uganda
Barriers to prompt and effective malaria treatment : what matters, Christian Lengeler,Swiss Tropical Institute
05.00 pm - 06:45 pm
Reinfection vs. Recrudescence in P. Falciparum Malaria: From Molecular Analysis to Clinical Impact, chaired by Anna Wang, MMV and Solomon Nwaka, WHO
WHY: In malaria endemic areas, people are often infected and re-infected with malaria several times during a transmission season. Re-infection and parasite recrudescence is a critical area of concern for healthcare workers, clinicians and malaria research scientists. How do we best use genotyping to distinguish recrudescent from new infections when evaluating the clinical efficacy of antimalarials?
SPEAKERS: Hans Peter Beck, Nick J White, Abdoulaye A Djimde and Grant Dorsey.
THURSDAY 8 NOV
08:00am - 09:45am
Results of a randomised, multicentre, Phase II, dose-ranging clinical study to assess the safety and efficacy of fixed dose, orally administered pyronaridine and artesunate in adult patients
PRESENTER: Srivicha Krudsood, Mahidol University